ABBV · 10-Q · 2026Q3 · Full report
Drug Pricing and Tariff Relief
AbbVie Inc. · 2026-11-03 · Importance 66 · Surprise 42 · In source text
In January 2026, AbbVie announced a voluntary agreement with the U.S. government to advance access and affordability while protecting investment in U.S. pharmaceutical innovation. AbbVie will provide low prices in Medicaid and expand affordable direct-to-patient offerings. It pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade. The U.S. government agreed to exempt AbbVie from tariffs and future price mandates for three years.
Key facts
- In January 2026, AbbVie agreed with the U.S. government to provide low prices in Medicaid and expand affordable direct-to-patient offerings; the government agreed to a three-year exemption for AbbVie from tariffs and future price mandates. source
- CMS selected Botox in January 2026 as one of 15 medicines for government-set prices in Medicare Parts B and D beginning in 2028; on October 29, 2026, a federal district court vacated the selection and enjoined CMS from publishing a maximum fair price, and the ruling is subject to government appeal. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | — | In January 2026, AbbVie agreed with the U.S. government to provide low prices in Medicaid and expand affordable direct-to-patient… |
| operating_income | positive | committed | — | In January 2026, AbbVie agreed with the U.S. government to provide low prices in Medicaid and expand affordable direct-to-patient… |
| revenue | positive | probable | — | CMS selected Botox in January 2026 as one of 15 medicines for government-set prices in Medicare Parts B and D beginning in 2028; on… |